Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
About Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
"L’IRCCS Ospedale San Raffaele è una struttura clinica-scientifica-universitaria di rilievo internazionale e di alta specializzazione per diverse importanti patologie, riconosciuta nel 1972 “Istituto di Ricovero e Cura a Carattere Scientifico” (IRCCS). La tematica della Medicina Molecolare è sempre stata l’elemento caratterizzante di questa Istituzione che ha scelto di focalizzare verso la comprensione dei processi molecolari e le applicazioni mediche delle scoperte della biologia molecolare con lo scopo di sviluppare terapie innovative per le patologie del sistema nervoso centrale e periferico, dell’apparato cardiovascolare e del metabolismo, per le patologie tumorali, le malattie infettive e immunomediate, le malattie genetiche e rare."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Incyte Corporation
7
Clinical Trials at Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
During the past decade, Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
2019-01-17
2023-03-30
Active, not recruiting
155
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
2019-06-03
2028-07-27
Recruiting
434
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
2021-01-26
2025-06-22
Recruiting
300
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
2021-05-27
2026-05-23
Recruiting
440
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
2022-01-14
2024-06-01
Recruiting
45
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
2021-07-12
2023-05-15
Active, not recruiting
4
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations
2022-05-20
2026-01-30
Recruiting
164
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele"
#1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "GOG Foundation" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were
collaborators in the rest 2 trials.
Clinical Trials Conditions at Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
According to Clinical.Site data, the most researched conditions in "Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele" are
"Myelofibrosis" (2 trials), "Adult-type Diffuse Gliomas" (1 trials), "Chronic Graft-versus-host Disease" (1 trials), "Endometrial Cancer" (1 trials) and "Glioblastoma" (1 trials). Many other conditions were trialed in "Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele" in a lesser frequency.
Clinical Trials Intervention Types at Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
Most popular intervention types in "Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele" are "Drug" (7 trials). Other intervention types were less common.
The name of intervention was led by "INCAGN02385" (2 trials), "INCAGN02390" (2 trials), "Pemigatinib" (2 trials), "epacadostat" (2 trials) and "retifanlimab" (2 trials). Other intervention names were less common.
Clinical Trials Genders at Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
The vast majority of trials in "Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele" are
6 trials for "All" genders and 1 trials for "Female" genders.
Clinical Trials Status at Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele
Currently, there are NaN active trials in "Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele".
undefined are not yet recruiting,
5 are recruiting,
2 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Istituto Di Ricovero E Cura A Carattere Scientifico (Irccs) Ospedale San Raffaele, 0 "Phase 1"
clinical trials were conducted, 5 "Phase 2" clinical
trials and 3 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".